ترجمه مقاله نقش ضروری ارتباطات 6G با چشم انداز صنعت 4.0
- مبلغ: ۸۶,۰۰۰ تومان
ترجمه مقاله پایداری توسعه شهری، تعدیل ساختار صنعتی و کارایی کاربری زمین
- مبلغ: ۹۱,۰۰۰ تومان
Abstract
The approval in the US and Europe of Eculizumab in 2007 marked a change in complement therapeutics, and with it the landscape for complement testing in the clinical immunology laboratory changed. The change had begun even before that when C1-Inhibitor preparations were approved in the 1980s in Europe. There are now two classes of approved drugs that may impact the immunology laboratory, with two dozen more with novel modalities and potential indications that are in various stages of development. Every pathway and about every component of complement has been targeted by these drug development programs, and the modalities of the drugs in development are diverse. These developments will likely result in more laboratories offering more complement testing, so this review looks forward to some of those possible changes in testing.
Conclusions
The rapid increase in therapeutics targeting complement is already putting pressure on immunology laboratories. This pressure includes the demand for more complement analyses, as well as the need to do that testing rapidly. The clinical immunologist may be increasingly called upon to evaluate what testing will be useful for which new therapeutic and for which disorder. With all the aforementioned complications, complement is a cascade of enzymes and proenzymes, something that coagulation laboratories have been adept at handling for years so clearly the challenge can be met. As more therapeutics are approved and are in use by patients, it is possible testing will be needed to determine the best drug for an individual patient. Individual diversity in complement genetics and component levels can mean that a different drug targeted at different part of the complement cascade may be better for an individual patient, even among those coping with the same disease [67]. In this way the clinical immunology laboratory may be called upon to perform complement testing to aid in the administration of precision medicine.